Mastoscopic sentinel lymph node biopsy in breast
cancer
Ding Boni,
Zhang Hongyan,
Li Xiaorong,
Qian Liyuan,
Chen Xuedong,
Wu Wei,
Wen Yanguang,
Zhao Yujun
Affiliations
Ding Boni
Department of General Surgery, The
Third Xiangya Hospital, Central South University, Changsha, Hunan,
410013, China
Zhang Hongyan
Department of General Surgery, The
Third Xiangya Hospital, Central South University, Changsha, Hunan,
410013, China
Li Xiaorong
Department of General Surgery, The
Third Xiangya Hospital, Central South University, Changsha, Hunan,
410013, China
Qian Liyuan
Department of General Surgery, The
Third Xiangya Hospital, Central South University, Changsha, Hunan,
410013, China
Chen Xuedong
Department of General Surgery, The
Third Xiangya Hospital, Central South University, Changsha, Hunan,
410013, China
Wu Wei
Department of General Surgery, The
Third Xiangya Hospital, Central South University, Changsha, Hunan,
410013, China
Wen Yanguang
Department of General Surgery, The
Third Xiangya Hospital, Central South University, Changsha, Hunan,
410013, China
Zhao Yujun
Department of Transplantation
Surgery, The Third Xiangya Hospital, Central South University, 138
Tongzipo Rd, Hexiyuelu Dist., Changsha, Hunan 410013, China
Background: Previous studies have demonstrated that mastoscopic sentinel lymph node biopsy (MSLNB) has good identification rate (IR) and low false negative rate (FNR). However, few studies have directly compared the surgical performance and peri- and post-operative factors of MSLNB with conventional sentinel lymph node biopsy (SLNB).
